AUTHORS
Kevin Zablonski, MD, Seong-Hwan Jun, PhD2, Frank Akwaa, MD3, William Joseph Archibald, MD, CPA4
AFFILIATIONS
1 University of Rochester Medical Center, Rochester, New York, United States
2 University of Rochester, Rochester, New York, United States
3 University of Rochester Medical Center, Rochester, New York, United States
4 University of Rochester Medical Center, Rochester, New York, United States
ABSTRACT
Background
Hereditary hemorrhagic telangiectasia (HHT) is a rare vascular disorder characterized by recurrent epistaxis, mucocutaneous telangiectasias, and visceral arteriovenous malformations (AVMs). Epistaxis occurs in up to 95% of patients, leading to iron deficiency anemia, impaired quality of life, and substantial healthcare utilization [Kritharis A, Haematologica 2018]. Annual healthcare costs in HHT approach $19,000–$38,000 per patient depending on disease severity, and current management relies on off-label agents such as bevacizumab [Al-Samkari H, American Journal of Hematology 2025]. Engasertib, a selective oral AKT inhibitor, was recently evaluated in a phase 2, randomized, placebo-controlled trial [Al-Samkari H, New England Journal of Medicine 2025], demonstrating a 28% reduction in epistaxis frequency and a 41% reduction in epistaxis duration at the 40 mg dose versus placebo. As the first agent to demonstrate placebo-controlled efficacy in HHT, engasertib has the potential to simultaneously reduce disease burden and healthcare costs, yet its economic value remains unknown.
Methods
We constructed a 4-state Markov cohort model in TreeAge Pro Healthcare [TreeAge Software 2025] comparing engasertib 40 mg daily versus best supportive care (BSC) from a US healthcare payer perspective over a lifetime horizon. Health states reflected disease severity as defined by hematologic support requirements: mild (no hematologic support), moderate (anemia requiring iron infusion support), severe (transfusion-dependent anemia), and death. The modelled cohort entered with a distribution of 15% mild, 55% moderate, and 30% severe, consistent with the trial population. BSC transition probabilities were informed by the placebo arm of the trial, which demonstrated minimal spontaneous improvement in disease severity. Engasertib transition probabilities were derived from the InHIBIT-Bleed study [Al-Samkari H, Haematologica 2021], scaled proportionally to its epistaxis severity score reduction relative to bevacizumab. Improvement transitions were modelled as active in year 1 only, reflecting the clinical assumption that engasertib either achieves disease control within the first year or does not. Utility and cost inputs were sourced from published HHT literature and claims data [Donaldson JW, Neurology 2015; Zarrabeitia R, Health and Quality of Life Outcomes 2017; Wang D, Blood Advances 2024] and inflated to 2026 US dollars.
Since engasertib has no established commercial price, a threshold analysis was conducted to identify the maximum annual drug cost at which the incremental cost-effectiveness ratio (ICER) remains below standard willingness-to-pay (WTP) thresholds. Probabilistic sensitivity analysis (PSA) was performed using 10,000 Monte Carlo iterations with beta distributions for transition probabilities and utilities, log-normal distributions for relative risks, and gamma distributions for costs.
Results
At zero drug acquisition cost, engasertib dominated BSC in the base case, producing 1.53 additional quality-adjusted life years (QALYs; 11.23 vs 9.70) at $81,369 lower total cost ($372,117 vs $453,486). PSA confirmed robustness of the dominance finding, with engasertib cost-effective in 99.99% of iterations at a $100,000/QALY threshold at zero drug cost. Threshold analysis demonstrated that engasertib would remain cost-effective at a WTP threshold of $100,000/QALY at annual drug prices up to $16,986, and at $150,000/QALY up to $22,527 per year. One-way sensitivity analysis identified the annual management costs in the severe HHT state, health state utility for severe HHT, and health state utility for moderate HHT as the primary drivers of model uncertainty.
Conclusion
This analysis demonstrates that engasertib 40 mg daily produces 1.53 additional QALYs at $81,369 lower total cost versus BSC, a clinically meaningful and economically compelling finding for a disease with no approved therapy. Cost-effectiveness at standard WTP thresholds would require annual drug prices of approximately $16,986–$22,527, with the true economic value of engasertib likely higher as the ongoing Phase 3 HEROIC trial provides direct demonstration of anemia and AVM-related outcomes. As the only oral agent with placebo-controlled efficacy in HHT and a favorable tolerability profile compared to existing off-label agents, engasertib represents a compelling therapeutic and economic advance for a patient population with significant unmet need.
DISCLOSURES
Kevin Zablonski, MD: No relevant conflicts of interest to declare.